Patents by Inventor H.S. PAGIRE

H.S. PAGIRE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Autophagy enhancer and use thereof
    Patent number: 10881642
    Abstract: Provided are a compound of chemical formula 1 or 2 and a use thereof. The compound can be advantageously used in the prevention or treatment of metabolic diseases including type 2 diabetes, insulin resistance, or obesity, on the basis of a mechanism of autophagy activation through the promotion of lysosome production.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 5, 2021
    Assignees: Industry-Academic Cooperation Foundation, Yonsei University, Gwangju Institute of Science and Technology
    Inventors: Myung-Shik Lee, Hyejin Lim, Young Eui Jeon, Jin Hee Ahn, H. S. Pagire
  • AUTOPHAGY ENHANCER AND USE THEREOF
    Publication number: 20190336483
    Abstract: Provided are a compound of chemical formula 1 or 2 and a use thereof. The compound can be advantageously used in the prevention or treatment of metabolic diseases including type 2 diabetes, insulin resistance, or obesity, on the basis of a mechanism of autophagy activation through the promotion of lysosome production.
    Type: Application
    Filed: June 29, 2017
    Publication date: November 7, 2019
    Applicants: Industry-Academic Cooperation Foundation, Yonsei University, Gwangju Institute of Science and Technology
    Inventors: Myung-Shik LEE, Hyejin LIM, Young Eui JEON, Jin Hee AHN, H.S. PAGIRE
  • Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient
    Patent number: 9321728
    Abstract: The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: April 26, 2016
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, HANDOK PHARMACEUTICALS CO., LTD.
    Inventors: Jin Hee Ahn, H. S. Pagire, Sang Dal Rhee, Ki Young Kim, Won Hoon Jung, Myung-Ae Bae, Jin Sook Song, Kwang-Rok Kim, Hyun Jung Kwak
  • NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT
    Publication number: 20150329504
    Abstract: The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.
    Type: Application
    Filed: April 25, 2013
    Publication date: November 19, 2015
    Inventors: Jin Hee AHN, H.S. PAGIRE, Sal Dal RHEE, Ki Young KIM, Won Hoon JUNG, Myung-Ae BAE, Jin Sook SONG, Kwang-Rok KIM, Hyun Jung KWAK